Onglyza® Patients at Potential Risk of Pancreatic Cancer
| December 1st, 2015
Onglyza® is a medication that’s made by AstraZeneca and is used to treat a large number of patients who suffer from Type II Diabetes. The U.S. Food and Drug Administration approved Onglyza’s use in 2009. Since that time, a number of reports have surfaced linking the medication to patients suffering adverse health events.
One of the dangers patients using the medication face is an Onglyza® pancreatic cancer risk. A study released two years ago in the medical journal, Diabetes, found patients who took drugs like Onglyza were at a 40 percent greater risk of developing pancreatic cancer than patients who didn’t use the medication. Furthermore, the study identified a rise in pre-cancerous pancreatic cell growth in users of Onglyza, as compared to others not taking the drug.
Earlier this year, a report was released by Reuters that found those who use the medication may be at risk of an increased rate of death. Since the research surfaced, AstraZeneca has vowed to “further review the data.”
If you’ve been harmed as the result of taking Onglyza, the Birmingham drug injury lawyers at Cory Watson Attorneys are here to help. Call us toll free for a free consultation at 1-877-562-0000. Take a look at our website to get more information about the resources and legal options a legal representative may be able to provide for you.